Novel Antibody-Drug Conjugate May Improve PFS in Advanced Breast Cancer
SYD985 may provide a new treatment option for patients with previously treated locally advanced or metastatic HER2-positive metastatic breast cancer.
All articles by Mark L. Fuerst
Ribociclib Improves Survival by More Than 1 Year in Advanced Breast Cancer
The overall survival benefit with ribociclib increased over time.
Immunotherapy Significantly Improved Survival in Recurrent/Metastatic Cervical Cancer
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.
Oncolytic Therapy Adds No Survival Benefit to PD-1 Treated Advanced Melanoma
Median OS was not reached for the T-VEC plus pembrolizumab arm and 49.2 months for the placebo plus pembrolizumab arm.
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
